Concerns of "cherry picking" were voiced (shocker) when AVXL chose to report EEG/ERP data before other data at the first interim report. As we saw on November 9th, those concerns were groundless. Giving an advance snapshot based on one measure for the patients who've been in the trial longest, and then following up that snapshot with more complete data once all participants have reached that milestone, simply appears to be the way the company is handling things.
The 12-week ADCS-ADL data released Nov 9 is unprecedented -- the world has never seen any drug or placebo effect that can show improvement in ADCS-ADL anywhere near what the 2-73 data showed. In fact the overwhelming majority show decline in that measure even when data is positive in MMSE and other cognitive measures.
The last thing the ADCS-ADL data suggests to me is cherry picking. It suggests that 2-73 is finding unprecedented success against Alzheimer's Disease. For the other measures (MMSE, EEG/ERP, & Cogstate) to suddenly reverse course in the face of great ADCS-ADL data, especially after the excellent 5-week data in those categories, strikes me as highly improbable. We'll know soon enough.
Market Data 
Markets 
AI
